AU2015274767B2 - Carbon monoxide-releasing molecules for therapeutic applications and methods of making and using thereof - Google Patents
Carbon monoxide-releasing molecules for therapeutic applications and methods of making and using thereof Download PDFInfo
- Publication number
- AU2015274767B2 AU2015274767B2 AU2015274767A AU2015274767A AU2015274767B2 AU 2015274767 B2 AU2015274767 B2 AU 2015274767B2 AU 2015274767 A AU2015274767 A AU 2015274767A AU 2015274767 A AU2015274767 A AU 2015274767A AU 2015274767 B2 AU2015274767 B2 AU 2015274767B2
- Authority
- AU
- Australia
- Prior art keywords
- group
- heteroaryl
- aryl
- cycloalkyl
- moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 *C(C(*)=C1c2c(*)cccc2)=C(*)C1=O Chemical compound *C(C(*)=C1c2c(*)cccc2)=C(*)C1=O 0.000 description 7
- UKPCWZDYXXTZQA-UHFFFAOYSA-N CC(C(C1C2N)c3cccc4cccc1c34)C2=O Chemical compound CC(C(C1C2N)c3cccc4cccc1c34)C2=O UKPCWZDYXXTZQA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B32/00—Carbon; Compounds thereof
- C01B32/40—Carbon monoxide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B37/00—Reactions without formation or introduction of functional groups containing hetero atoms, involving either the formation of a carbon-to-carbon bond between two carbon atoms not directly linked already or the disconnection of two directly linked carbon atoms
- C07B37/10—Cyclisation
- C07B37/12—Diels-Alder reactions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Carbon And Carbon Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462009451P | 2014-06-09 | 2014-06-09 | |
| US62/009,451 | 2014-06-09 | ||
| PCT/US2015/034948 WO2015191616A1 (en) | 2014-06-09 | 2015-06-09 | Carbon monoxide-releasing molecules for therapeutic applications and methods of making and using thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2015274767A1 AU2015274767A1 (en) | 2017-01-05 |
| AU2015274767B2 true AU2015274767B2 (en) | 2020-04-16 |
Family
ID=54834205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015274767A Ceased AU2015274767B2 (en) | 2014-06-09 | 2015-06-09 | Carbon monoxide-releasing molecules for therapeutic applications and methods of making and using thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10300069B2 (enExample) |
| EP (1) | EP3151919B1 (enExample) |
| JP (1) | JP6670763B2 (enExample) |
| KR (1) | KR20170007857A (enExample) |
| CN (1) | CN106794362B (enExample) |
| AU (1) | AU2015274767B2 (enExample) |
| CA (1) | CA2950007A1 (enExample) |
| WO (1) | WO2015191616A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015191616A1 (en) | 2014-06-09 | 2015-12-17 | Georgia State University Research Foundation, Inc. | Carbon monoxide-releasing molecules for therapeutic applications and methods of making and using thereof |
| US11420994B2 (en) | 2016-11-16 | 2022-08-23 | Georgia State University Research Foundation, Inc. | Carbon-monoxide-releasing molecules and therapeutic applications thereof |
| KR102373273B1 (ko) * | 2017-04-18 | 2022-03-15 | 기초과학연구원 | 고분자형 젤과 이의 제조방법, 및 이를 포함하는 물품 |
| WO2018231841A1 (en) | 2017-06-12 | 2018-12-20 | Georgia State University Research Foundation, Inc. | Enzyme-triggered carbon monoxide releasing molecules |
| US20180369278A1 (en) * | 2017-06-23 | 2018-12-27 | The Regents Of The University Of Michigan | Carbon monoxide-based therapies and implantable devices for the treatment of vascular disease |
| WO2019032879A1 (en) * | 2017-08-09 | 2019-02-14 | Georgia State University Research Foundation, Inc. | CARBON MONOXIDE RELEASE MOLECULES DISCHARGED BY PHYSIOLOGICAL STIMULI |
| WO2019084323A1 (en) | 2017-10-25 | 2019-05-02 | Georgia State University Research Foundation, Inc. | CHEMICAL RELEASE SYSTEM DELIVERED BY ENRICHMENT |
| CN109306049B (zh) * | 2018-09-28 | 2020-12-01 | 中国热带农业科学院农产品加工研究所 | 植物油-壳聚糖基可生物降解pua及其制备方法和应用 |
| CN113365617B (zh) * | 2018-10-16 | 2025-12-23 | 乔治亚州立大学研究基金会股份有限公司 | 用于医学疾病治疗的一氧化碳前药 |
| CN113559071B (zh) * | 2021-08-18 | 2022-12-27 | 苏州大学 | 一种co靶向递送系统及其构建方法与应用 |
| EP4275682A1 (en) * | 2022-05-12 | 2023-11-15 | Institut National De La Sante Et De La Recherche Medicale - Inserm | Carbon monoxide-releasing molecule (corm) or composition thereof for use in the treatment or the prevention of an intestinal dysbiosis in a subject |
| CN117534840A (zh) * | 2022-08-02 | 2024-02-09 | 巴迪脉通医疗科技(苏州)有限公司 | 一种可释放co的医用高分子及其制备方法及应用 |
| WO2025090901A1 (en) * | 2023-10-26 | 2025-05-01 | Georgia State University Research Foundation, Inc. | Ros-activated co prodrugs for cancer treatment |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5670664A (en) * | 1995-09-08 | 1997-09-23 | University Of Maryland Biotechnology Institute | Photosensitive organic compounds that release carbon monoxide upon illumination |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2319518A1 (en) | 2002-02-04 | 2011-05-11 | ALFAMA-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda. | Use of CO-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases |
| US7807619B2 (en) | 2004-11-01 | 2010-10-05 | The Regents Of The University Of California | Compositions and methods for modification of biomolecules |
| US8519122B2 (en) | 2010-02-12 | 2013-08-27 | The Regents Of The University Of California | Compositions and methods for modification of biomolecules |
| WO2015191616A1 (en) | 2014-06-09 | 2015-12-17 | Georgia State University Research Foundation, Inc. | Carbon monoxide-releasing molecules for therapeutic applications and methods of making and using thereof |
-
2015
- 2015-06-09 WO PCT/US2015/034948 patent/WO2015191616A1/en not_active Ceased
- 2015-06-09 US US15/317,705 patent/US10300069B2/en active Active
- 2015-06-09 CN CN201580042734.9A patent/CN106794362B/zh active Active
- 2015-06-09 KR KR1020177000227A patent/KR20170007857A/ko not_active Withdrawn
- 2015-06-09 JP JP2016571722A patent/JP6670763B2/ja active Active
- 2015-06-09 AU AU2015274767A patent/AU2015274767B2/en not_active Ceased
- 2015-06-09 CA CA2950007A patent/CA2950007A1/en not_active Abandoned
- 2015-06-09 EP EP15807244.7A patent/EP3151919B1/en active Active
-
2019
- 2019-05-27 US US16/423,094 patent/US10751344B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5670664A (en) * | 1995-09-08 | 1997-09-23 | University Of Maryland Biotechnology Institute | Photosensitive organic compounds that release carbon monoxide upon illumination |
Non-Patent Citations (1)
| Title |
|---|
| KITAMURA et al., "A New Hypervalent Iodine Precursor of a Highly Strained Cyclic Alkyne. Generation and Trapping Reactions of Bicyclo[2.2.1]hept-2-en-5-yne", Journal of Organic Chemistry, (1999), vol. 64, pages 680 - 681 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3151919A1 (en) | 2017-04-12 |
| CA2950007A1 (en) | 2015-12-17 |
| US10751344B2 (en) | 2020-08-25 |
| US20170128456A1 (en) | 2017-05-11 |
| WO2015191616A1 (en) | 2015-12-17 |
| KR20170007857A (ko) | 2017-01-20 |
| EP3151919A4 (en) | 2018-02-21 |
| US20190350937A1 (en) | 2019-11-21 |
| EP3151919B1 (en) | 2023-08-30 |
| JP6670763B2 (ja) | 2020-03-25 |
| AU2015274767A1 (en) | 2017-01-05 |
| US10300069B2 (en) | 2019-05-28 |
| CN106794362B (zh) | 2021-07-06 |
| CN106794362A (zh) | 2017-05-31 |
| JP2017528416A (ja) | 2017-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10751344B2 (en) | Carbon monoxide-releasing molecules for therapeutic applications and methods for the preparation and use thereof | |
| US11420994B2 (en) | Carbon-monoxide-releasing molecules and therapeutic applications thereof | |
| JP6871864B2 (ja) | イソオキサゾリル置換ベンズイミダゾール類 | |
| CN107750251B (zh) | 异噁唑基取代的咪唑并吡啶 | |
| AU2009308511B2 (en) | Transition metal complexes of a bis[thiohydrazide amide] compound | |
| TW201039815A (en) | Compositions and methods for the treatment of inflammation | |
| WO2006097625A1 (fr) | NOUVEAUX DÉRIVÉS D'IMIDAZO[1,5-a]PYRIDINES, LEUR PROCÉDÉ DE PRÉPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT. | |
| KR20210102887A (ko) | 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제 | |
| US12396972B2 (en) | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | |
| EP2958569B1 (fr) | Hétérocycles phosphorés analogues de sucres à activité antimétastatique | |
| US11730712B2 (en) | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | |
| US20200283382A1 (en) | Carbon monoxide-releasing molecules triggered by physiological stimuli | |
| ES2382000T3 (es) | Profármacos de carbomato de aciloxialquilo, procedimientos de síntesis y uso | |
| WO2004080455A1 (ja) | 抗菌剤と抗ガン剤 | |
| EP3237015B1 (fr) | Derives hydroxybisphosphoniques hydrosolubles de la doxorubicine | |
| CN114478318A (zh) | 二腈异佛尔酮衍生物、其制备方法及应用 | |
| JP2019516725A (ja) | がんを処置するためのプロパルギル基を含む生体直交型化合物 | |
| WO2024247648A1 (ja) | 腫瘍の治療剤及び複合体 | |
| CN119977961A (zh) | 一种protac化合物及其制备方法和作为靶向tau的降解剂的应用 | |
| CN116731305A (zh) | 一种抗肿瘤大环内酯聚合物及其制备方法和应用 | |
| CN116726010A (zh) | 一种大环内酯衍生物在制备抑制促炎细胞因子作用剂药物的应用 | |
| JP2018535231A (ja) | チアジアゾール誘導体類のdpp−iv阻害剤の結晶及びその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |